The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.
Danaher Corporation (DHR)
Common Stock · Currency in USD · XNYS
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Company Info
SIC3823
Composite FIGIBBG000BH3JF8
CIK0000313616
IPODec 29, 1978
Sectorindustrial instruments for measurement, display, and control
Highlights
Market Cap$135.26B
EPS$5.12
P/E Ratio37.24
Revenue$23.98B
Gross Profit$14.09B
Net Income$3.63B
Employees60,000
WSO707,699,419
Phone(202) 828-0850
Websitehttps://www.danaher.com
Related Tickers
CSL
Carlisle Companies, Inc.
$331.11 0.00%
TMO
Thermo Fisher Scientific, Inc.
$489.90 0.00%
GFF
Griffon Corp
$71.42 0.00%
CR
Crane Company
$168.00 0.00%
A
Agilent Technologies Inc.
$115.48 0.00%
MTD
Mettler-Toledo International
$1.26K 0.00%
RGEN
Repligen Corp
$117.78 0.00%
TECH
Bio-Techne Corp.
$53.13 0.00%
IQV
IQVIA Holdings Inc.
$173.26 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Danaher Corporation, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Danaher Corporation (DHR) has returned -16.47% so far this year and 8.34% over the past 12 months. Looking at the last ten years, DHR has achieved an annualized return of 10.26%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
DHR
1M-5.51%
6M-11.11%
YTD-16.47%
1Y8.34%
5Y-3.77%
10Y10.26%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Danaher Corporation (DHR) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.34% | -4.01% | -8.85% | 0.29% | ||||||||
| 2025 | -3.51% | -4.70% | -2.13% | -2.77% | -4.27% | 4.95% | 0.09% | 5.37% | -3.08% | 8.39% | 6.48% | 1.04% |
| 2024 | 4.37% | 5.76% | -1.28% | -1.24% | 4.28% | -2.87% | 10.84% | -3.56% | 4.11% | -11.83% | -3.72% | -4.12% |
| 2023 | -1.28% | -6.63% | 2.58% | -5.25% | -4.00% | 4.48% | 7.35% | 3.89% | -7.44% | -12.33% | 16.41% | 4.02% |
| 2022 | -12.63% | -4.54% | 6.89% | -14.61% | 5.46% | -6.61% | 14.61% | -6.92% | -4.42% | -3.67% | 7.75% | -3.67% |
| 2021 | 5.71% | -8.28% | 1.88% | 12.60% | -0.23% | 5.65% | 11.00% | 8.35% | -5.92% | 1.56% | 2.79% | 2.72% |
| 2020 | 4.49% | -10.75% | -4.75% | 22.57% | 2.62% | 6.69% | 15.07% | 0.72% | 4.83% | 5.77% | -3.34% | -1.71% |
| 2019 | 9.11% | 14.50% | 3.50% | -0.53% | -0.49% | 8.11% | -2.46% | 0.89% | 2.76% | -4.46% | 5.23% | 4.77% |
| 2018 | 8.69% | -3.11% | 0.16% | 2.77% | -1.07% | -1.42% | 4.48% | 0.92% | 4.82% | -8.96% | 10.21% | -6.68% |
| 2017 | 6.99% | 1.18% | -1.18% | -2.72% | 1.64% | -1.03% | -3.88% | 2.31% | 2.89% | 7.29% | 2.15% | -1.77% |
| 2016 | 2.55% | 1.68% | 3.30% | 6.00% | 0.21% | -3.87% | 0.76% | -0.69% | -0.37% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Danaher Corporation (DHR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of DHR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Danaher Corporation volatility is 1.91%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 83.46B | 77.54B | 84.49B | 84.35B | 83.18B | 76.16B | 62.08B | 47.83B | 46.65B | 45.30B | 48.22B | 36.99B | 34.67B | 32.94B | 29.95B | 19.60B |
| Equity Attributable To Parent (USD) | 52.53B | 49.54B | 53.49B | 50.08B | 45.17B | 39.77B | 30.27B | 28.21B | 26.36B | 23.00B | 23.69B | 23.38B | 22.39B | 19.02B | 16.90B | 11.63B |
| Equity Attributable To Noncontrolling Interest (USD) | 7.00M | 7.00M | 4.00M | 8.00M | 10.00M | 11.00M | 11.30M | 12.30M | 9.60M | 74.00M | 73.70M | 71.70M | 66.10M | 67.40M | 66.99M | - |
| Equity (USD) | 52.54B | 49.55B | 53.49B | 50.09B | 45.18B | 39.78B | 30.28B | 28.23B | 26.37B | 23.08B | 23.76B | 23.45B | 22.45B | 19.08B | 16.97B | 11.63B |
| Other Non-current Liabilities (USD) | 5.70B | 5.19B | 4.32B | 6.19B | 7.69B | 7.78B | 5.14B | 5.02B | 4.97B | 3.08B | 5.42B | 4.67B | 4.19B | 4.31B | 3.50B | - |
| Long-term Debt (USD) | 18.42B | 16.01B | 18.40B | 19.68B | 22.18B | 21.20B | 21.73B | 9.74B | 10.52B | 12.27B | 12.87B | 3.47B | 3.50B | 5.34B | 5.31B | - |
| Noncurrent Liabilities (USD) | 24.12B | 21.19B | 22.72B | 25.87B | 29.87B | 28.98B | 26.87B | 14.76B | 15.49B | 15.34B | 18.29B | 8.15B | 7.69B | 9.65B | 8.81B | 5.20B |
| Other Current Liabilities (USD) | 5.62B | 5.70B | 7.15B | 7.01B | 6.77B | 6.01B | 4.00B | 3.81B | 3.83B | 5.96B | 5.20B | 4.49B | - | - | - | - |
| Wages (USD) | 1.19B | 1.10B | 1.13B | 1.38B | 1.37B | 1.39B | 931.30M | 1.03B | 961.00M | 914.10M | 968.70M | 911.40M | - | - | - | - |
| Current Liabilities (USD) | 6.81B | 6.80B | 8.27B | 8.39B | 8.14B | 7.40B | 4.93B | 4.84B | 4.79B | 6.87B | 6.17B | 5.40B | 4.53B | 4.21B | 4.17B | 2.76B |
| Liabilities (USD) | 30.92B | 27.99B | 31.00B | 34.26B | 38.01B | 36.38B | 31.80B | 19.61B | 20.28B | 22.22B | 24.46B | 13.54B | 12.22B | 13.86B | 12.98B | 7.97B |
| Other Non-current Assets (USD) | 47.36B | 44.49B | 45.25B | 44.21B | 44.90B | 37.82B | 24.43B | 26.55B | 25.68B | 24.46B | 26.29B | 17.99B | 17.10B | 16.87B | 15.74B | 10.58B |
| Intangible Assets (USD) | 17.82B | 18.57B | 20.75B | 20.30B | 22.84B | 21.28B | 9.75B | 11.67B | 11.67B | 11.82B | 11.27B | 7.37B | 6.25B | 6.34B | 5.84B | 2.66B |
| Fixed Assets (USD) | 5.53B | 4.99B | 4.55B | 3.96B | 3.79B | 3.26B | 2.30B | 2.51B | 2.45B | 2.35B | 2.83B | 2.20B | 2.21B | 2.14B | 2.10B | 1.14B |
| Noncurrent Assets (USD) | 70.71B | 68.05B | 70.55B | 68.47B | 71.54B | 62.36B | 36.49B | 40.74B | 39.80B | 38.63B | 40.39B | 27.56B | 25.56B | 25.35B | 23.68B | 14.37B |
| Other Current Assets (USD) | 10.27B | 7.17B | 11.34B | 12.77B | 8.88B | 11.51B | 23.97B | 5.18B | 5.01B | 4.96B | 5.74B | 7.60B | 7.33B | 5.77B | 4.49B | 4.23B |
| Inventory (USD) | 2.49B | 2.33B | 2.59B | 3.11B | 2.77B | 2.29B | 1.63B | 1.91B | 1.84B | 1.71B | 2.10B | 1.83B | 1.78B | 1.81B | 1.78B | 993.02M |
| Current Assets (USD) | 12.76B | 9.50B | 13.94B | 15.88B | 11.65B | 13.80B | 25.60B | 7.09B | 6.85B | 6.67B | 7.84B | 9.43B | 9.11B | 7.59B | 6.27B | 5.22B |
| Assets (USD) | 83.46B | 77.54B | 84.49B | 84.35B | 83.18B | 76.16B | 62.08B | 47.83B | 46.65B | 45.30B | 48.22B | 36.99B | 34.67B | 32.94B | 29.95B | 19.60B |
News and Insights
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.
The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.
The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.
Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share, payable on April 24, 2026 to shareholders of record on March 27, 2026.
Deal Dispatch: Starboard Targets TripAdvisor, His & Hers Expands, Mister Car Wash Goes Privatepositive
Major M&A activity continues across multiple sectors: Starboard Value pushes TripAdvisor toward a sale, Hims & Hers acquires Eucalyptus for $1.15B to expand internationally, Danaher buys Masimo for $9.9B, Mister Car Wash goes private via Leonard Green for $3.1B, and Devon Energy completes a $21.4B merger with Coterra Energy. Meanwhile, Saks Global struggles with vendor shipments during bankruptcy, and Warner Bros. Discovery rejects Paramount's hostile bid.
Danaher agreed to acquire Masimo Corporation for $180 per share in an all-cash deal valued at $9.9 billion. The acquisition is expected to be accretive to earnings by $0.15-$0.20 in the first full year and approximately $0.70 by the fifth year, with projected annual synergies exceeding $175 million. Analysts view the deal as having sound financial rationale with strong recurring revenue and margin improvement potential.
Danaher Corp. is reportedly nearing a $9.9 billion acquisition of Masimo Corp., with an announcement potentially coming as early as Tuesday. The deal represents a significant premium to Masimo's $7 billion market cap and follows governance changes driven by activist investors. Masimo shares surged 34.51% on the news, while Danaher shares fell 5.22% in premarket trading.